Childhood ocular safety after postnatal exposure to topical dexamethasone during retinopathy of prematurity screening.

Twenty-four infants (median gestational age 25.0 weeks, range 22.6-27.7 weeks; 58% male) were examined at a median age of 2.9 years (range 1.1-5.0 years).

Dexamethasone eye drops were initiated mainly for severe retinopathy of prematurity at a median postmenstrual age of 35.1 weeks (range 32.0-52.0 weeks) and given for a median duration of 28 days (range 4-136 days).

One child had a unilateral peripheral lens opacity without visual significance.